Economical evaluation of darunavir plus low dose ritonavir intreatment-experienced HIV-1-infected patients

被引：0
|
作者：
Vorobiev, P. [1 ]
Avksentieva, M. [1 ]
Lesnicheva, M. [2 ]
机构：
[1] Moscow Med Acad, Moscow, Russia
[2] Russian Soc Pharmacoecon & Outcomes Res, Moscow, Russia
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70317-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A98 / A98
页数：1
相关论文
共 50 条
  • [41] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS
    Arathoon, E.
    Schneider, S.
    Baraldi, E.
    Lim, P. L.
    Opravil, M.
    Van De Casteele, T.
    Lavreys, L.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (01) : 12 - 17
  • [42] Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
    Kakuda, Thomas
    Sekar, Vanitha
    Vis, Peter
    Coate, Bruce
    Ryan, Robert
    Anderson, David
    De La Rosa, Guy
    Mrus, Joseph
    AIDS RESEARCH AND TREATMENT, 2012, 2012
  • [43] A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults
    Avihingsanon, A.
    van der Lugt, J.
    Kerr, S. J.
    Gorowara, M.
    Chanmano, S.
    Ohata, P.
    Lange, J.
    Cooper, D. A.
    Phanuphak, P.
    Burger, D. M.
    Ruxrungtham, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) : 402 - 408
  • [44] Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
    Karen Moeremans
    Lieven Annemans
    Mickael Löthgren
    Gabriele Allegri
    Veronique Wyffels
    Lindsay Hemmet
    Karin Caekelbergh
    Erik Smets
    PharmacoEconomics, 2010, 28 : 107 - 128
  • [45] Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients
    Gulick, Roy M.
    Fatkenheuer, Gerd
    Burnside, Robert
    Hardy, W. David
    Nelson, Mark R.
    Goodrich, James
    Mukwaya, Geoffrey
    Portsmouth, Simon
    Heera, Jayvant R.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (01) : 78 - 81
  • [46] Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children
    Rudin, Christoph
    Wolbers, Marcel
    Nadal, David
    Rickenbach, Martin
    Bucher, Heiner C.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2010, 95 (06) : 478 - 481
  • [47] Efficacy of a Reduced Dose of Darunavir/Ritonavir in a Small Cohort of Antiretroviral-Naive HIV-Infected Patients
    Lanzafame, Massimiliano
    Lattuada, Emanuela
    Rigo, Fabio
    Vento, Sandro
    AIDS PATIENT CARE AND STDS, 2013, 27 (06) : 315 - 316
  • [48] Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up
    Lanzafame, Massimiliano
    Lattuada, Emanuela
    Rigo, Fabio
    Ferrari, Anna
    Hill, Andrew
    Vento, Sandro
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (02) : 627 - 630
  • [49] A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
    Josephine Mauskopf
    Lieven Annemans
    Andrew M. Hill
    Erik Smets
    PharmacoEconomics, 2010, 28 : 1 - 16
  • [50] A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
    Mauskopf, Josephine
    Annemans, Lieven
    Hill, Andrew M.
    Smets, Erik
    PHARMACOECONOMICS, 2010, 28 : 1 - 16
12345